Blockading NKG2A may promote anti-tumor immunity by unleashing dysfunctional CD8+T cells in tumors, and targeting NKG2A+CD8+T cells is a promising approach for future anti-lung cancer immunotherapy. This evidence concerns the gene CD8A and lung cancer.